|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liu W, Quan B, Lu S, Tang B, Li M, Chen R,
Ren Z and Yin X: First-line systemic treatment strategies for
unresectable hepatocellular carcinoma: A systematic review and
network meta-analysis of randomized clinical trials. Front Oncol.
11:7710452021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Meyer T, Fox R, Ma YT, Ross PJ, James MW,
Sturgess R, Stubbs C, Stocken DD, Wall L, Watkinson A, et al:
Sorafenib in combination with transarterial chemoembolisation in
patients with unresectable hepatocellular carcinoma (TACE 2): A
randomised placebo-controlled, double-blind, phase 3 trial. Lancet
Gastroenterol Hepatol. 2:565–575. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sun J, Zhou C, Zhao Y, Zhang X, Chen W,
Zhou Q, Hu B, Gao D, Raatz L, Wang Z, et al: Quiescin sulfhydryl
oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular
carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2
activation. Redox Biol. 41:1019422021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang Y, Tan Y, Liu S, Yin H, Duan J, Fan
L, Zhao X and Jiang B: Implications of Withaferin A for the
metastatic potential and drug resistance in hepatocellular
carcinoma cells via Nrf2-mediated EMT and ferroptosis. Toxicol Mech
Methods. 33:47–55. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sun X, Ou Z, Chen R, Niu X, Chen D, Kang R
and Tang D: Activation of the p62-Keap1-NRF2 pathway protects
against ferroptosis in hepatocellular carcinoma cells. Hepatology.
63:173–184. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH,
Chen PJ and Cheng AL: Activation of phosphatidylinositol
3-kinase/Akt signaling pathway mediates acquired resistance to
sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther.
337:155–161. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gao L, Morine Y, Yamada S, Saito Y,
Ikemoto T, Tokuda K, Takasu C, Miyazaki K and Shimada M: Nrf2
signaling promotes cancer stemness, migration, and expression of
ABC transporter genes in sorafenib-resistant hepatocellular
carcinoma cells. PLoS One. 16:e02567552021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang Q, Ching B, Xue Q, Gao Q, Huang A,
Wang K and Tang N: GSTZ1 sensitizes hepatocellular carcinoma cells
to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis.
Cell Death Dis. 12:4262021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen F, Wang H, Zhu J, Zhao R, Xue P,
Zhang Q, Nelson MB, Qu W, Feng B and Pi J: Camptothecin suppresses
NRF2-ARE activity and sensitises hepatocellular carcinoma cells to
anticancer drugs. Br J Cancer. 117:1495–1506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tian B, Lu ZN and Guo XL: Regulation and
role of nuclear factor-E2-related factor 2 (Nrf2) in multidrug
resistance of hepatocellular carcinoma. Chem Biol Interact.
280:70–76. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tebay LE, Robertson H, Durant ST, Vitale
SR, Penning TM, Dinkova-Kostova AT and Hayes JD: Mechanisms of
activation of the transcription factor Nrf2 by redox stressors,
nutrient cues, and energy status and the pathways through which it
attenuates degenerative disease. Free Radic Biol Med. 88:108–146.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao AM, Ke ZP, Shi F, Sun GC and Chen H:
Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin
by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway. Chem Biol
Interact. 206:100–108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Najafi M, Mortezaee K and Majidpoor J:
Cancer stem cell (CSC) resistance drivers. Life Sci.
234:1167812019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shibue T and Weinberg RA: EMT, CSCs, and
drug resistance: The mechanistic link and clinical implications.
Nat Rev Clin Oncol. 14:611–629. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Huang T, Song X, Xu D, Tiek D, Goenka A,
Wu B, Sastry N, Hu B and Cheng SY: Stem cell programs in cancer
initiation, progression, and therapy resistance. Theranostics.
10:8721–8743. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Niture SK, Khatri R and Jaiswal AK:
Regulation of Nrf2-an update. Free Radic Biol Med. 66:36–44. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
He F, Ru X and Wen T: NRF2, a
transcription factor for stress response and beyond. Int J Mol Sci.
21:47772020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He F, Antonucci L and Karin M: NRF2 as a
regulator of cell metabolism and inflammation in cancer.
Carcinogenesis. 41:405–416. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tonelli C, Chio IIC and Tuveson DA:
Transcriptional regulation by Nrf2. Antioxid Redox Signal.
29:1727–1745. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang DD, Lo SC, Cross JV, Templeton DJ
and Hannink M: Keap1 is a redox-regulated substrate adaptor protein
for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol.
24:10941–10953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hayes JD, McMahon M, Chowdhry S and
Dinkova-Kostova AT: Cancer chemoprevention mechanisms mediated
through the Keap1-Nrf2 pathway. Antioxid Redox Signal.
13:1713–1748. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gao L, Morine Y, Yamada S, Saito Y,
Ikemoto T, Tokuda K, Miyazaki K, Okikawa S, Takasu C and Shimada M:
The BAFF/NFκB axis is crucial to interactions between
sorafenib-resistant HCC cells and cancer-associated fibroblasts.
Cancer Sci. 112:3545–3554. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu MC, Ji JA, Jiang ZY and You QD: The
Keap1-Nrf2-ARE pathway as a potential preventive and therapeutic
target: An update. Med Res Rev. 36:924–963. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Robertson H, Dinkova-Kostova AT and Hayes
JD: NRF2 and the ambiguous consequences of its activation during
initiation and the subsequent stages of tumourigenesis. Cancers
(Basel). 12:36092020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu Q, Zhao S, Meng F, Wang H, Sun L, Li
G, Gao F and Chen F: Nrf2 down-regulation by camptothecin favors
inhibiting invasion, metastasis and angiogenesis in hepatocellular
carcinoma. Front Oncol. 11:6611572021. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kitamura H and Motohashi H: NRF2 addiction
in cancer cells. Cancer Sci. 109:900–911. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tang XJ, Han M, Yang B, Shen YQ, He ZG, Xu
DH and Gao JQ: Nanocarrier improves the bioavailability, stability
and antitumor activity of camptothecin. Int J Pharm. 477:536–545.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tang W, Chen Z, Zhang W, Cheng Y, Zhang B,
Wu F, Wang Q, Wang S, Rong D, Reiter FP, et al: The mechanisms of
sorafenib resistance in hepatocellular carcinoma: Theoretical basis
and therapeutic aspects. Signal Transduct Target Ther. 5:872020.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zheng A, Chevalier N, Calderoni M, Dubuis
G, Dormond O, Ziros PG, Sykiotis GP and Widmann C: CRISPR/Cas9
genome-wide screening identifies KEAP1 as a sorafenib, lenvatinib,
and regorafenib sensitivity gene in hepatocellular carcinoma.
Oncotarget. 10:7058–7070. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tang X, Wang H, Fan L, Wu X, Xin A, Ren H
and Wang XJ: Luteolin inhibits Nrf2 leading to negative regulation
of the Nrf2/ARE pathway and sensitization of human lung carcinoma
A549 cells to therapeutic drugs. Free Radic Biol Med. 50:1599–1609.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Murakami Y, Sugiyama K, Ebinuma H,
Nakamoto N, Ojiro K, Chu PS, Taniki N, Saito Y, Teratani T, Koda Y,
et al: Dual effects of the Nrf2 inhibitor for inhibition of
hepatitis C virus and hepatic cancer cells. BMC Cancer. 18:6802018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Arlt A, Sebens S, Krebs S, Geismann C,
Grossmann M, Kruse ML, Schreiber S and Schäfer H: Inhibition of the
Nrf2 transcription factor by the alkaloid trigonelline renders
pancreatic cancer cells more susceptible to apoptosis through
decreased proteasomal gene expression and proteasome activity.
Oncogene. 32:4825–4835. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang XJ, Hayes JD, Henderson CJ and Wolf
CR: Identification of retinoic acid as an inhibitor of
transcription factor Nrf2 through activation of retinoic acid
receptor alpha. Proc Natl Acad Sci U S A. 104:19589–19594. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bailly C: Irinotecan: 25 years of cancer
treatment. Pharmacol Res. 148:1043982019. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
de Lucas Chazin E, da Rocha Reis R, Junior
WT, Moor LF and Vasconcelos TR: An overview on the development of
new potentially active camptothecin analogs against cancer. Mini
Rev Med Chem. 14:953–962. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sass G, Barikbin R and Tiegs G: The
multiple functions of heme oxygenase-1 in the liver. Z
Gastroenterol. 50:34–40. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Leung HW, Lau EYT, Leung CON, Lei MML, Mok
EHK, Ma VWS, Cho WCS, Ng IOL, Yun JP, Cai SH, et al: NRF2/SHH
signaling cascade promotes tumor-initiating cell lineage and drug
resistance in hepatocellular carcinoma. Cancer Lett. 476:48–56.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dai C, Chen X, Li J, Comish P, Kang R and
Tang D: Transcription factors in ferroptotic cell death. Cancer
Gene Ther. 27:645–656. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang G and Zhang G: Upregulation of FoxP4
in HCC promotes migration and invasion through regulation of EMT.
Oncol Lett. 17:3944–3951. 2019.PubMed/NCBI
|
|
41
|
Wang Y, Shi J, Chai K, Ying X and Zhou BP:
The role of snail in EMT and tumorigenesis. Curr Cancer Drug
Targets. 13:963–972. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Giannelli G, Koudelkova P, Dituri F and
Mikulits W: Role of epithelial to mesenchymal transition in
hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gheldof A and Berx G: Cadherins and
epithelial-to-mesenchymal transition. Prog Mol Biol Transl Sci.
116:317–336. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Al Khatib AM, Mărgăritescu C, Taisescu O,
Andreiana BC, Florescu MM and Ciurea RN: Immunoexpression of
E-cadherin, snail and twist in colonic adenocarcinomas. Rom J
Morphol Embryol. 60:531–536. 2019.PubMed/NCBI
|
|
45
|
Tian Y, Qi P, Niu Q and Hu X: Combined
snail and E-cadherin predicts overall survival of cervical
carcinoma patients: Comparison among various epithelial-mesenchymal
transition proteins. Front Mol Biosci. 7:222020. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhao H, Cheng X, Yu J and Li Y:
Stabilization of snail maintains the sorafenib resistance of
hepatocellular carcinoma cells. Arch Biochem Biophys.
699:1087542021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chen HA, Kuo TC, Tseng CF, Ma JT, Yang ST,
Yen CJ, Yang CY, Sung SY and Su JL: Angiopoietin-like protein 1
antagonizes MET receptor activity to repress sorafenib resistance
and cancer stemness in hepatocellular carcinoma. Hepatology.
64:1637–1651. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
van Malenstein H, Dekervel J, Verslype C,
Van Cutsem E, Windmolders P, Nevens F and van Pelt J: Long-term
exposure to sorafenib of liver cancer cells induces resistance with
epithelial-to-mesenchymal transition, increased invasion and risk
of rebound growth. Cancer Lett. 329:74–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhao CX, Luo CL and Wu XH: Hypoxia
promotes 786-O cells invasiveness and resistance to sorafenib via
HIF-2α/COX-2. Med Oncol. 32:4192014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Liu H, Wang M, Liang N and Guan L: PDCD2
sensitizes HepG2 cells to sorafenib by suppressing
epithelialmesenchymal transition. Mol Med Rep. 19:2173–2179.
2019.PubMed/NCBI
|
|
51
|
Chen W, Yang J, Zhang Y, Cai H, Chen X and
Sun D: Regorafenib reverses HGF-induced sorafenib resistance by
inhibiting epithelial-mesenchymal transition in hepatocellular
carcinoma. FEBS Open Bio. 9:335–347. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mir N, Jayachandran A, Dhungel B, Shrestha
R and Steel JC: Epithelial-to-mesenchymal transition: A mediator of
sorafenib resistance in advanced hepatocellular carcinoma. Curr
Cancer Drug Targets. 17:698–706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ji X, Wang H, Zhu J, Zhu L, Pan H, Li W,
Zhou Y, Cong Z, Yan F and Chen S: Knockdown of Nrf2 suppresses
glioblastoma angiogenesis by inhibiting hypoxia-induced activation
of HIF-1α. Int J Cancer. 135:574–584. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D,
Lee YM, Ku SK, Jung Y and Kwak MK: NRF2 blockade suppresses colon
tumor angiogenesis by inhibiting hypoxia-induced activation of
HIF-1α. Cancer Res. 71:2260–2275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Tramontano L, Cavaliere C, Salvatore M and
Brancato V: The role of non-gaussian models of diffusion weighted
MRI in hepatocellular carcinoma: A systematic review. J Clin Med.
10:26412021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhou Y, Yang G, Gong XQ, Tao YY, Wang R,
Zheng J, Yang C, Peng J, Yang L, Li JD and Zhang XM: A study of the
correlations between IVIM-DWI parameters and the histologic
differentiation of hepatocellular carcinoma. Sci Rep. 11:103922021.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Le Bihan D, Breton E, Lallemand D, Grenier
P, Cabanis E and Laval-Jeantet M: MR imaging of intravoxel
incoherent motions: Application to diffusion and perfusion in
neurologic disorders. Radiology. 161:401–407. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Granata V, Fusco R, Filice S, Catalano O,
Piccirillo M, Palaia R, Izzo F and Petrillo A: The current role and
future prospectives of functional parameters by diffusion weighted
imaging in the assessment of histologic grade of HCC. Infect Agent
Cancer. 13:232018. View Article : Google Scholar : PubMed/NCBI
|
